Frank Pallone actually said...

This is an important hearing, not only in terms of what is happening to biosimilars, but just the larger issue of drug pricing.

Biosimilars hold enormous potential to offer patients with serious and life-threatening diseases access to more treatment options and potent...

I do worry that it is important in the case of biosimilars or generics that that continue to be a way of reducing drug pricing.

I worry that this inappropriately treats biosimilars like generic drugs and will disincentivize manufacturers from entering the biosimilars ...